UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

The cost effectiveness of teriparatide as a first-line treatment for glucocorticoid-induced and postmenopausal osteoporosis patients in Sweden

BMC musculoskeletal disorders, 2012-10, Vol.13 (1), p.213-213, Article 213

2012

Volltextzugriff (PDF)

The Budget Impact of Increased Use of Febuxostat in the Management of Gout: A US Health Plan Managed Care Pharmacy and Medical Costs Perspective

Clinical therapeutics, 2016-07, Vol.38 (7), p.1710-1725

2016

Volltextzugriff (PDF)

Assessing the Cost-effectiveness of a Hypothetical Disease-modifying Therapy With Limited Duration for the Treatment of Early Symptomatic Alzheimer Disease

Clinical therapeutics, 2022-11, Vol.44 (11), p.1449-1462

2022

Volltextzugriff (PDF)

Budget impact analysis of insulin therapies and associated delivery systems

American journal of health-system pharmacy, 2012-06, Vol.69 (11), p.958-965

2012

Volltextzugriff (PDF)

ANTIBACTERIAL ENVELOPE IS ASSOCIATED WITH MEDICAL COST SAVINGS IN PATIENTS AT HIGH RISK FOR CARDIOVASCULAR IMPLANTABLE ELECTRONIC DEVICE INFECTION

Journal of the American College of Cardiology, 2017-03, Vol.69 (11), p.382-382

2017

Volltextzugriff (PDF)

Cost-effectiveness model comparing olanzapine and other oral atypical antipsychotics in the treatment of schizophrenia in the United States

Cost effectiveness and resource allocation, 2009-04, Vol.7 (4), p.4-4, Article 4

2009

Volltextzugriff (PDF)

Estimating the Economically Justifiable Price of Limited-Duration Treatment with Donanemab for Early Symptomatic Alzheimer’s Disease in the United States

Neurology and therapy, 2024-09

2024

Volltextzugriff (PDF)

Febuxostat in the management of gout: a cost-effectiveness analysis

Journal of medical economics, 2016-03, Vol.19 (3), p.265-276

2016

Volltextzugriff (PDF)

Cost-effectiveness of olanzapine long-acting injection in the treatment of patients with schizophrenia in the United States: a micro-simulation economic decision model

Current medical research and opinion, 2011-04, Vol.27 (4), p.713-730

2011

Volltextzugriff (PDF)

Using Common Random Numbers in Health Care Cost-Effectiveness Simulation Modeling

Health services research, 2013-08, Vol.48 (4), p.1508-1525

2013

Volltextzugriff (PDF)

Cost-effectiveness of several atypical antipsychotics in orally disintegrating tablets compared with standard oral tablets in the treatment of schizophrenia in the United States

Journal of medical economics, 2012, Vol.15 (3), p.531-547

2012

Volltextzugriff (PDF)

Cost effectiveness of rosuvastatin in patients at risk of cardiovascular disease based on findings from the JUPITER trial

Journal of medical economics, 2010-09, Vol.13 (3), p.428-437

2010

Volltextzugriff (PDF)

Comparison of vials and prefilled pens of a rapid-acting insulin analog on pharmacy budgets in a long-term care setting

The Consultant pharmacist, 2014-12, Vol.29 (12), p.813-822

2014

Volltextzugriff (PDF)

The Adsorption of Perfluorooctane Sulfonate onto Sand, Clay, and Iron Oxide Surfaces

Journal of chemical and engineering data, 2007-07, Vol.52 (4), p.1165-1170

2007

Volltextzugriff (PDF)

DNA Methylation signatures underpinning blood neutrophil to lymphocyte ratio during first week of human life

Nature communications, 2024-09, Vol.15 (1), p.8167-14, Article 8167

2024

Volltextzugriff (PDF)

Golimumab in patients with active rheumatoid arthritis after treatment with tumour necrosis factor α inhibitors (GO-AFTER study): a multicentre, randomised, double-blind, placebo-controlled, phase III trial

The Lancet (British edition), 2009-07, Vol.374 (9685), p.210-221

2009

Volltextzugriff (PDF)

Preparing for Life: Plasma Proteome Changes and Immune System Development During the First Week of Human Life

Frontiers in immunology, 2020-10, Vol.11, p.578505-578505

2020

Volltextzugriff (PDF)

Efficacy and safety of tabalumab, an anti-B-cell-activating factor monoclonal antibody, in patients with rheumatoid arthritis who had an inadequate response to methotrexate therapy: results from a phase III multicentre, randomised, double-blind study

Annals of the rheumatic diseases, 2015-08, Vol.74 (8), p.1567-1570

2015

Volltextzugriff (PDF)

AB0027 PHARMACOKINETICS AND SAFETY OF CT-P47, A PROPOSED TOCILIZUMAB BIOSIMILAR, IN COMPARISON WITH INTRAVENOUS EU-APPROVED TOCILIZUMAB AND US-LICENSED TOCILIZUMAB; A PHASE 1, RANDOMIZED, DOUBLE-BLIND, THREE-ARM, SINGLE-DOSE STUDY IN HEALTHY JAPANESE SUBJECTS

Annals of the rheumatic diseases, 2024-06, Vol.83 (Suppl 1), p.1239-1239

2024

Volltextzugriff (PDF)

Early cellular and molecular signatures correlate with severity of West Nile virus infection

iScience, 2023-12, Vol.26 (12), p.108387-108387, Article 108387

2023

Volltextzugriff (PDF)

BCG vaccination–induced emergency granulopoiesis provides rapid protection from neonatal sepsis

Science translational medicine, 2020-05, Vol.12 (542)

2020

Volltextzugriff (PDF)

Minimal disease activity for rheumatoid arthritis: a preliminary definition

Journal of rheumatology, 2005-10, Vol.32 (10), p.2016

2005

Volltextzugriff (PDF)

Rheumatoid arthritis associated autoantibodies in patients with synovitis of recent onset

Arthritis research, 2000-01, Vol.2 (3), p.236-243, Article 236

2000

Volltextzugriff (PDF)

POS0634 PHARMACOKINETICS, USABILITY AND SAFETY OF TOCILIZUMAB BIOSIMILAR (CT-P47) ADMINISTERED SUBCUTANEOUSLY BY AUTO-INJECTOR OR PRE-FILLED SYRINGE

Annals of the rheumatic diseases, 2024-06, Vol.83 (Suppl 1), p.765-766

2024

Volltextzugriff (PDF)

Treating Rheumatoid Arthritis to Target: multinational recommendations assessment questionnaire

Annals of the rheumatic diseases, 2011-11, Vol.70 (11), p.1999-2002

2011

Volltextzugriff (PDF)

1 – 25 von 45

Suche als RSS-Feed

Aktive Filter

PublikationsformArtikel

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(42)
Mit Volltextzugriff
(32)

Sprache

Englisch
(45)

Erscheinungsjahr

n.n

Thema

Humans
(28)
Science & Technology
(26)
Life Sciences & Biomedicine
(22)
Female
(12)
Male
(11)
Rheumatology
(11)
Patients
(8)
Treatment Outcome
(7)
United States
(7)
Adult
(6)
Aged
(6)
Biological And Medical Sciences
(6)
Cost-Benefit Analysis
(6)
Medical Sciences
(6)
Middle Aged
(6)
Monoclonal Antibodies
(6)
Rheumatoid Arthritis
(6)
Severity Of Illness Index
(6)
Clinical Trials
(5)
Diseases Of The Osteoarticular System
(5)

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 30 Tagen
(1)
... seit 90 Tagen
(4)

Menü

Weitere Dienste

Einstellungen

The cost effectiveness of teriparatide as a first-line treatment for glucocorticoid-induced and postmenopausal osteoporosis patients in Sweden

The Budget Impact of Increased Use of Febuxostat in the Management of Gout: A US Health Plan Managed Care Pharmacy and Medical Costs Perspective

Assessing the Cost-effectiveness of a Hypothetical Disease-modifying Therapy With Limited Duration for the Treatment of Early Symptomatic Alzheimer Disease

Budget impact analysis of insulin therapies and associated delivery systems

ANTIBACTERIAL ENVELOPE IS ASSOCIATED WITH MEDICAL COST SAVINGS IN PATIENTS AT HIGH RISK FOR CARDIOVASCULAR IMPLANTABLE ELECTRONIC DEVICE INFECTION

Cost-effectiveness model comparing olanzapine and other oral atypical antipsychotics in the treatment of schizophrenia in the United States

Estimating the Economically Justifiable Price of Limited-Duration Treatment with Donanemab for Early Symptomatic Alzheimer’s Disease in the United States

Febuxostat in the management of gout: a cost-effectiveness analysis

Cost-effectiveness of olanzapine long-acting injection in the treatment of patients with schizophrenia in the United States: a micro-simulation economic decision model

Using Common Random Numbers in Health Care Cost-Effectiveness Simulation Modeling

Cost-effectiveness of several atypical antipsychotics in orally disintegrating tablets compared with standard oral tablets in the treatment of schizophrenia in the United States

Cost effectiveness of rosuvastatin in patients at risk of cardiovascular disease based on findings from the JUPITER trial

Comparison of vials and prefilled pens of a rapid-acting insulin analog on pharmacy budgets in a long-term care setting

The Adsorption of Perfluorooctane Sulfonate onto Sand, Clay, and Iron Oxide Surfaces

DNA Methylation signatures underpinning blood neutrophil to lymphocyte ratio during first week of human life

Golimumab in patients with active rheumatoid arthritis after treatment with tumour necrosis factor α inhibitors (GO-AFTER study): a multicentre, randomised, double-blind, placebo-controlled, phase III trial

Preparing for Life: Plasma Proteome Changes and Immune System Development During the First Week of Human Life

Efficacy and safety of tabalumab, an anti-B-cell-activating factor monoclonal antibody, in patients with rheumatoid arthritis who had an inadequate response to methotrexate therapy: results from a phase III multicentre, randomised, double-blind study

AB0027 PHARMACOKINETICS AND SAFETY OF CT-P47, A PROPOSED TOCILIZUMAB BIOSIMILAR, IN COMPARISON WITH INTRAVENOUS EU-APPROVED TOCILIZUMAB AND US-LICENSED TOCILIZUMAB; A PHASE 1, RANDOMIZED, DOUBLE-BLIND, THREE-ARM, SINGLE-DOSE STUDY IN HEALTHY JAPANESE SUBJECTS

Early cellular and molecular signatures correlate with severity of West Nile virus infection

BCG vaccination–induced emergency granulopoiesis provides rapid protection from neonatal sepsis

Minimal disease activity for rheumatoid arthritis: a preliminary definition

Rheumatoid arthritis associated autoantibodies in patients with synovitis of recent onset

POS0634 PHARMACOKINETICS, USABILITY AND SAFETY OF TOCILIZUMAB BIOSIMILAR (CT-P47) ADMINISTERED SUBCUTANEOUSLY BY AUTO-INJECTOR OR PRE-FILLED SYRINGE

Treating Rheumatoid Arthritis to Target: multinational recommendations assessment questionnaire

Aktive Filter

Suchergebnisse filtern